Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 29CNS 23Breast 22Gastrointestinal 21Lymphoid 12Head & Neck 9Thoracic 6Gynecologic 6Other hematologic neoplasm 5Sarcoma 3Tumor-Agnostic 2Plasma cell 2Other solid neoplasm 2Endocrine 2Dermatologic 2Myeloid 1

Conditions

Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Magnetic Resonance Imaging × Dermatologic × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT01557881 2020-02-24

Positron Emission Tomography/Magnetic Resonance Imaging in Patients

Case Comprehensive Cancer Center

Phase NA Terminated
98 enrolled 5 charts
DermatologicGastrointestinalHead & NeckLymphoidThoracic

Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡